A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine a new approach to preventing a serious problem after
transplant called graft vs. host disease (abbreviated as GVHD).
This is a single-arm, phase I/II, study of Pacritinib with Sirolimus and Tacrolimus
(PAC/SIR/TAC) for the prevention of acute GVHD after matched related and unrelated allogeneic
hematopoietic cell transplantation (alloHCT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute